LATOZINEMAB
UNII IKT0XSS2XB

Substance Identification & Data

This profile provides standardized clinical and technical data for Latozinemab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) IKT0XSS2XB.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2376132-27-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

IKT0XSS2XB

CAS Registry Number

2376132-27-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LATOZINEMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C179098

National Cancer Institute reference terminology for clinical and research data.

INN ID

11584

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

KL-93

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Latozinemab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LATOZINEMAB

Common Names & Synonyms

IMMUNOGLOBULIN G1 (239-ALANINE,240-ALANINE,336-SERINE), ANTI-(HUMAN SORTILIN-1) (HUMAN MONOCLONAL AL001 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AL001 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS SORT1 (SORTILIN 1, GP95, NT3)), HOMO SAPIENS MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-452) (VH (HOMO SAPIENS IGHV4-38-2*01 (99.0%) -(IGHD) -IGHJ6*01 (100%)) CDR-IMGT (9.7.15) (26-34.52-58.97-111) (1-122) -HOMO SAPIENS IGHG1*01 G1M17,1, G1V40 CH2 A1.3, A1.2, S116 (CH1 K120 (219) (123-220), HINGE 1-15 (221-235), CH2 L1.3>A (239), L1.2>A (240), P116>S (336) (236-345), CH3 D12 (361), L14 (363) (346-450), CHS (451-452)) (123-452)), (225-219')-DISULFIDE WITH KAPPA LIGHT CHAIN HOMO SAPIENS (1'-219') (V-KAPPA (HOMO SAPIENS IGKV2-28*01 (93.0%) -IGKJ4*01 (100%)) CDR-IMGT (11.3.9) (27-37.55-57.94-102) (1'-112') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (158), V101 (196) (113'-219')); DIMER (231-231'':234-234'')-BISDISULFIDE, PRODUCED IN A GLUTAMINE SYNTHETASE-CHINESE HAMSTER OVARY (CHO) CELL BASED EXPRESSION SYSTEM, GSKO CHOK1SV, GLYCOFORM ALFA

LATOZINEMAB [INN]

LATOZINEMAB [USAN]

LATOZINEMAB [WHO-DD]